Claims for Patent: 9,115,342

Summary for Patent: 9,115,342

Title:	Method for purifying cardiomyocytes or programmed cardiomyocytes derived from stem cells or fetuses
Abstract:	An object of the present invention is to develop a method for purify cardiomyocytes at a high degree of purification and at a high yield from a cell mixture comprising cardiomyocytes derived from fetuses and stem cells using various features which have not been previously expected to be used for purification of cardiomyocytes or which are newly found, wherein said method is carried out without undergoing any genetic modification or without adding any special proteins or biologically active agents.
Inventor(s):	Hattori; Fumiyuki (Mitaka, JP), Fukuda; Keiichi (Tokyo, JP)
Assignee:	DAIICHI SANKYO COMPANY (Tokyo, JP) KEIO UNIVERSITY (Tokyo, JP)
Application Number:	12/162,684
Patent Claims:	1. A method of selecting cardiomyocytes and/or Brachyury+/Nkx2.5-cells capable of differentiating into cardiomyocytes from a cell mixture containing cardiomyocytes, Brachyury+/Nkx2.5-cells, and non-cardiomyocyte cells comprising: Culturing the cell mixture in a culture medium under the following conditions: (i) a sugar-free condition or a condition wherein sugar content is 111.20 .mu.M or less; and (ii) one or more conditions selected from the group consisting of a low calcium condition, a low nutritional condition, a lactic acid-supplemented condition, an aspartic acid/glutamic acid-supplemented condition, and a pyruvic acid-supplemented condition to select the cardiomyocytes and/or Brachyury+/Nkx2.5-cells from the cell mixture, wherein the cell mixture is derived from totipotent cells, pluripotent cells, or stem cell having similar characteristics to those of embryonic stem cell through differentiation induction, wherein the low nutritional condition is a condition where the content of each nutritional component of the cultured medium is reduced to 10% or less of that of a culture medium selected from the group consisting of RPMI culture medium, DMEM culture medium, MEM culture medium, F12 culture medium, and .alpha.-MEM culture medium, and wherein the stem cells having similar characteristics to those of embryonic stem cells have surface markers specific for embryonic stem cells, have embryonic stem cell specific gene expression, and/or have an ability to form a teratoma. 2. The method of claim 1, further comprising eliminating dead cells adhered to the cardiomyocytes and/or the Brachyury+/Nkx 2.5-cells by treating the cell mixture with a collagenase. 3. The method of claim 2, wherein the dead cells are eliminated based on the filet that the specific gravity of the dead cells is higher than that of the cardiomyocytes and/or the Brachyury+/Nkx2.5-cells. 4. The method of claim 1, wherein the condition (ii) of the culture medium is a lactic acid-supplemented condition. 5. The method claim 1, wherein the condition (ii) of the culture medium is an aspartic acid/glutamic acid-supplemented condition. 6. The method of claim 1, wherein the condition (ii) of the culture medium is a pyruvic acid-supplemented condition. 7. The method of claim 1, wherein the cell mixture is prepared by the following steps of: inducing differentiation of embryonic stem cells or stem cells having similar characteristics to those of embryonic stem cells in a culture medium; forming embryoid bodies comprising the Brachyury+/Nkx2.5-cells; and preparing the cell mixture by culturing the embryoid bodies under a low-serum -supplemented condition and/or a mildly-acidic pH condition, wherein the low-serum -supplemented condition is serum-free condition, or a condition wherein the concentration of serum or serum components is reduced to less than 10% of serum or serum components supplemented to the culture medium used in the step of inducing differentiation. 8. A method for selecting cardiomyocytes and/or Brachyury+/Nkx2.5-cells capable of differentiating into cardiomyocytes derived from embryonic stem cells comprising: inducing differentiation of embryonic stem cells in a first culture medium to form embryoid bodies comprising the Brachyury+/Nkx2.5-cells; then preparing a cell mixture comprising the Brachyury+/Nkx2.5-cells by culturing the embryoid bodies in a second culture medium under a low-serum-supplemented condition and a mildly acidic pH condition, wherein the low-serum-supplemented condition is serum-free condition, or a condition wherein the concentration of serum or serum components is reduced to less than 10% of serum or serum components supplemented to the first culture medium used in the process for obtaining the embryoid bodies; and continuing the culture of the cell mixture in the same culture medium to obtain the cardiomyocytes and/or the Brachyury+/Nkx2.5-cells. 9. The method of claim 1, wherein the low calcium condition is a condition wherein the calcium concentration in the culture medium ranges between 0.3-1.3 mM. 10. The method of claim 1, wherein the lactic acid -supplemented condition is a condition wherein 0.1-5 mM of lactic acid is supplemented to the culture medium. 11. The method of claim 1, wherein the aspartic acid/glutamic acid-supplemented condition is a condition wherein 20-100 mg/L of aspartic acid and 20-100 mg/L of glutamic acid are supplemented to the culture medium. 12. The method of claim 1, wherein the pyruvic acid -supplemented condition is a condition wherein 0.5-5 mM of pyruvic acid is supplemented to the culture medium. 13. The method of claim 7, wherein the mildly-acidic pH condition is a condition of pH 6.5. 14. The method of claim 1, wherein the sugar is glucose. 15. The method of claim 1, wherein the stem cells having similar characteristics to those of embryonic stem cells are embryonic germ cells (EG cells) produced from primordial germ cells, germline stem cells (GS cells) produced from testicular germ cells, or induced pluripotent stem cells (iPS cells) produced from somatic cells. 16. The method of claim 15, wherein the stem cells having similar characteristics to those of embryonic stem cells are induced pluripotent stem cells (iPS cells). 17. The method of claim 7, wherein the concentration of serum or serum components is 0 to 1% in the low-serum-supplemented condition. 18. The method of claim 8, wherein the concentration of serum or serum components is 0 to 1% in the low-serum-supplemented condition.

Details for Patent 9,115,342

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Smith & Nephew, Inc.	SANTYL	collagenase	Ointment	101995	06/04/1965		2026-01-31